KRAS mutation was significantly associated with three tumor suppressor genes, TP53, CDKN2A, and SMAD4, genes describing specific molecular subtypes, and according to Qian et al., patients who accumulated a greater number of altered driver genes had worse DFS and OS [13]. This evidence concerns the gene TP53 and neoplasm.